Trial Profile
A Phase I, Open Label, Randomized, Parallel Group, Multicentre Study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] During 28 Days in Patients With HFmrEF or HFpEF and eGFR in the Range of ≥40 and ≤70 mL/Min/1.73m2
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Balcinrenone (Primary) ; Spironolactone
- Indications Heart failure
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 30 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 02 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2020 Planned number of patients changed from 60 to 65.